Activation of Peroxisome Proliferator-activated Receptors Alpha and Gamma1 Inhibits Human Smooth Muscle Cell Proliferation

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2003 Jul 5

PMID 12841350

Citations 6

Authors

Peter Zahradka

Natalia Yurkova

Brenda Litchie

Michael C Moon

Dario F Del Rizzo

Carla G Taylor

Affiliations

Soon will be listed here.

Abstract

Atherosclerotic lesions occur as a result of excess lipid deposition within the vascular tissues. The peroxisome proliferator-activated receptors (PPARs) present in adipose and hepatic tissues have been shown to promote fatty acid oxidation and lipid storage. An immunohistochemical assessment of PPARalpha and PPARgamma revealed both proteins were also present in the medial and intimal layers of human arteries, predominately in regions containing smooth muscle cells. In agreement with this observation, smooth muscle cells isolated from these vessels were found by RT-PCR to express both PPARalpha and PPARgamma1. The functionality of these receptors was tested with selective PPAR agonists. Mitogenic stimulation of smooth muscle cell proliferation was blocked by 15d-PGJ2, a PPARgamma agonist, as well as by WY14643, a PPARalpha agonist. These data indicate PPAR activation by selective agonists could influence lesion progression directly, as well as indirectly through reductions in serum lipoprotein and triglyceride levels.

Citing Articles

Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract.

Galiazzo G, Giancola F, Stanzani A, Fracassi F, Bernardini C, Forni M Histochem Cell Biol. 2018; 150(2):187-205.

PMID: 29882158 DOI: 10.1007/s00418-018-1684-7.

Atheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDL.

Fan A, Wu X, Wu H, Li L, Huang R, Zhu Y PLoS One. 2014; 9(1):e85337.

PMID: 24465540 PMC: 3896367. DOI: 10.1371/journal.pone.0085337.

MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration.

Sarkar J, Gou D, Turaka P, Viktorova E, Ramchandran R, Raj J Am J Physiol Lung Cell Mol Physiol. 2010; 299(6):L861-71.

PMID: 20693317 PMC: 3006273. DOI: 10.1152/ajplung.00201.2010.

PPARs and the cardiovascular system.

Hamblin M, Chang L, Fan Y, Zhang J, Chen Y Antioxid Redox Signal. 2008; 11(6):1415-52.

PMID: 19061437 PMC: 2737093. DOI: 10.1089/ars.2008.2280.

Conjugated linoleic acid reduces hepatic steatosis, improves liver function, and favorably modifies lipid metabolism in obese insulin-resistant rats.

Noto A, Zahradka P, Yurkova N, Xie X, Nitschmann E, Ogborn M Lipids. 2007; 41(2):179-88.

PMID: 17707984 DOI: 10.1007/s11745-006-5086-6.

References

Palakurthi S, Aktas H, Grubissich L, Mortensen R, Halperin J . Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res. 2001; 61(16):6213-8. View

Jones D, Ding X, Daynes R . Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem. 2001; 277(9):6838-45. DOI: 10.1074/jbc.M106908200. View

Chinetti G, Fruchart J, Staels B . Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z Kardiol. 2001; 90 Suppl 3:125-32. DOI: 10.1007/s003920170034. View

Betz E, Quack G . Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis. Vasa. 1990; 19(2):157-60. View

Marx N, Mackman N, Schonbeck U, Yilmaz N, Hombach V, Libby P . PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation. 2001; 103(2):213-9. DOI: 10.1161/01.cir.103.2.213. View

Diep Q, Touyz R, Schiffrin E . Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension. 2000; 36(5):851-5. DOI: 10.1161/01.hyp.36.5.851. View

Li A, Brown K, Silvestre M, Willson T, Palinski W, Glass C . Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000; 106(4):523-31. PMC: 380255. DOI: 10.1172/JCI10370. View

Ma X, Stoffregen D, Wheelock G, Rininger J, Babish J . Discordant hepatic expression of the cell division control enzyme p34cdc2 kinase, proliferating cell nuclear antigen, p53 tumor suppressor protein, and p21Waf1 cyclin-dependent kinase inhibitory protein after WY14,643.... Mol Pharmacol. 1997; 51(1):69-78. DOI: 10.1124/mol.51.1.69. View

Miwa Y, Sasaguri T, Inoue H, Taba Y, Ishida A, Abumiya T . 15-Deoxy-Delta(12,14)-prostaglandin J(2) induces G(1) arrest and differentiation marker expression in vascular smooth muscle cells. Mol Pharmacol. 2000; 58(4):837-44. DOI: 10.1124/mol.58.4.837. View

10.

Benson S, Wu J, Padmanabhan S, Kurtz T, Pershadsingh H . Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone. Am J Hypertens. 2000; 13(1 Pt 1):74-82. DOI: 10.1016/s0895-7061(99)00148-x. View

11.

Zahradka P, Harris K, Triggs-Raine B, Lamontagne G, Leblanc N . PCR-based analysis of voltage-gated K+ channels in vascular smooth muscle. Mol Cell Biochem. 1995; 145(1):39-44. DOI: 10.1007/BF00925711. View

12.

Del Rizzo D, Yurkova N, Moon M, Litchie B, Zahradka P . Platelet-derived growth factor-induced expression of c-fos in human vascular smooth muscle cells: implications for long-term graft patency. Ann Thorac Surg. 2002; 74(1):90-5. DOI: 10.1016/s0003-4975(02)03600-7. View

13.

Chiba Y, Ogita T, Ando K, Fujita T . PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells. Biochem Biophys Res Commun. 2001; 286(3):541-6. DOI: 10.1006/bbrc.2001.5361. View

14.

Schoonjans K, Staels B, Auwerx J . The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1996; 1302(2):93-109. DOI: 10.1016/0005-2760(96)00066-5. View

15.

Rubins H, Robins S, Collins D, Fye C, Anderson J, Elam M . Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341(6):410-8. DOI: 10.1056/NEJM199908053410604. View

16.

Clarke S . Polyunsaturated fatty acid regulation of gene transcription: a mechanism to improve energy balance and insulin resistance. Br J Nutr. 2000; 83 Suppl 1:S59-66. DOI: 10.1017/s0007114500000969. View

17.

Qi C, Zhu Y, Reddy J . Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys. 2001; 32 Spring:187-204. DOI: 10.1385/cbb:32:1-3:187. View

18.

Chinetti G, Griglio S, Antonucci M, Torra I, Delerive P, Majd Z . Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998; 273(40):25573-80. DOI: 10.1074/jbc.273.40.25573. View

19.

Torra I, Chinetti G, Duval C, Fruchart J, Staels B . Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol. 2001; 12(3):245-54. DOI: 10.1097/00041433-200106000-00002. View

20.

Law R, Goetze S, Xi X, Jackson S, Kawano Y, Demer L . Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation. 2000; 101(11):1311-8. DOI: 10.1161/01.cir.101.11.1311. View